LAS VEGAS, Jan. 26 Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that it has retired almost $6 million worth of notes which had been provided by Enable Capital Management, LLC and their affiliates between 2007 and 2009.
Advertisement
"It is important for shareholders to understand the importance of reducing debt and strengthening our balance sheet," said Matthew Schissler, CEO and co-founder, Cord Blood America. "We truly appreciate Enable Capital Management for financing critical growth periods for CBAI. We are happy to report that all of our obligations with Enable Capital Management are paid in full." The total debt retired since January of 2009 is approaching $11 million.
Advertisement
Mr. Schissler also thanked the more than 200 investors and guests who attended the Company's Grand Opening in Las Vegas on Friday, January 22. "It was good to show our shareholders our laboratory, our storage facilities, and for them to meet our management team," Cord Blood America's co-founder and CEO said.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate,'' "believe,'' "expect,'' "future,'' "intend,'' "plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 [email protected]
SOURCE Cord Blood America, Inc.
